A Phase I Study of a Recombinant Chimeric Protein Composed of Circularly Permuted IL-4 and a Mutated Form of the Pseudomonas Exotoxin Termed IL-4(38-37)-PE38KDEL (IL-4 Toxin) for the Treatment of Recurrent Malignant Astrocytoma
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2017
At a glance
- Drugs MDNA 55 (Primary)
- Indications Astrocytoma; Glioblastoma
- Focus Adverse reactions
- 14 Nov 2017 According to a Medicenna Therapeutics media release, results were presented at Cancer Prevention and Research Conference held from November 13-14, 2017 in Austin.
- 14 Nov 2017 Results published in the Medicenna Therapeutics media release.
- 24 Sep 2005 New trial record.